Optimising stroke prevention in non-valvular atrial fibrillation

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 15, 2006, Pages 2079-2094

  Ederhy, Stéphane ^a   Cohen, Ariel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Aspirin; Atrial fibrillation; Stroke; Vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; WARFARIN;

ADULT; AGED; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; HEART ATRIUM FIBRILLATION; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; ELECTRIC COUNTERSHOCK; EXPERT TESTIMONY; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 33750122957     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.15.2079     Document Type: Review

References (129)

1. WOLF PA, DAWBER TR, THOMAS HE Jr, KANNEL WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology (1978) 28:973-977. (Pubitemid 8401525)
2. WOLF PA, ABBOTT RD, KANNEL WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22:983-988.
3. ASINGER RW, KOEHLER J, PEARCE LA et al.: Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation. II. Dense spontaneous echocardiographic contrast (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J. Am. Soc. Echocardiogr. (1999) 12:1088-1096.
4. GOLDMAN ME, PEARCE LA, HART RG et al.: Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation. I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J. Am. Soc. Echocardiogr. (1999) 12:1080-1087.
5. BLACKSHEAR JL, PEARCE LA, HART RG et al.: Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke (1999) 30:834-840. (Pubitemid 29156377)
6. WOLF PA, MITCHELL JB, BAKER CS, KANNEL WB, D'AGOSTINO RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. (1998) 158:229-234.
7. THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Arch. Intern. Med. (1992) 116:1-5.
8. BENJAMIN EJ, WOLF PA, D'AGOSTINO RB, SILBERSHATZ H, KANNEL WB, LEVY D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98:946-952. • This study examines mortality in patients who developed AF during follow up, and demonstrated that AF was associated with an approximate twofold mortality increase. (Pubitemid 28446646)
9. HALPERIN JL, HART RG: Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke (1988) 19:937-941. (Pubitemid 18203982)
10. BOGOUSSLAVSKY J, VAN MELLE G, REGLI F, KAPPENBERGER L: Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology (1990) 40:1046-1050. (Pubitemid 20213969)
11. ZABALGOITIA M, HALPERIN JL, PEARCE LA, BLACKSHEAR JL, ASINGER RW, HART RG; STROKE PREVENTION IN ATRIAL FIBRILLATION III INVESTIGATORS: Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. (1998) 31:1622-1626. • A cross-sectional analysis of TEE featured among participants of the SPAF-III study, demonstrating that TEE findings were independently associated with a high thromboembolic risk in AF patients.
12. PETTY GW, BROWN RD Jr, WHISNANT JP, SICKS JD, O'FALLON WM, WIEBERS DO: Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke (1999) 30:2513-2516.
13. PENADO S, CANO S, ACHA O, HERNANDEZ JL, RIANCHO JA: Stroke severity in patients with atrial fibrillation. Am. J. Med. (2002) 112:572-574.
14. LAMASSA M, DI CARLO AA, PRACUCCI G et al.: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the European Community Stroke Project). Stroke (2001) 32:392-398. (Pubitemid 32155224)
15. LIN HJ, WOLF PA, KELLY-HAYES M et al.: Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 27:1760-1764.
16. HYLEK EM, GO AS, CHANG Y et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. (2003) 349:1019-2617.
17. AGMON Y, KHANDHERIA BK, GENTILE F, SEWARD JB: Echocardiographic assessment of the left atrial appendage. J. Am. Coll. Cardiol. (1999) 34:1867-1877. • An exhaustive review article on LAA and dysfunction and its clinical implication.
18. MANNING WJ, SILVERMAN DI, WAKSMONSKI CA, OETTGEN P, DOUGLAS PS: Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch. Intern. Med. (1995) 155:2193-2198.
19. CHIMOWITZ MI, DEGEORGIA MA, POOLE RM, HEPNER A, ARMSTRONG WM: Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke (1993) 24(7):1015-1019. (Pubitemid 23201459)
20. STODDARD MF, DAWKINS PR, PRINCE CR, AMMASH NM: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. (1995) 25:452-459.
21. FATKIN D, KELLY RP, FENELEY MP: Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J. Am. Coll. Cardiol. (1994) 23:961-969.
22. GRIMM RA, STEWART WJ, MALONEY JD et al.: Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J. Am. Coll. Cardiol. (1993) 22:1359-1366.
23. KLEIN AL, MURRAY RD, GRIMM RA: Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J. Am. Coll. Cardiol. (2001) 37:691-704.
24. MANNING WJ, LEEMAN DE, GOTCH PJ, COME PC: Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. (1989) 13:617-623.
25. BERGER M, SCHWEITZER P: Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am. J. Cardiol. (1998) 82:1545-1547.
26. LIP GY: Does atrial fibrillation confer a hypercoagulable state? Lancet (1995) 346:1313-1314.
27. CONWAY DS, PEARCE LA, CHIN BS, HART RG, LIP GY: Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation (2002) 106:1962-1967. (Pubitemid 35176302)
28. LIP GY, LIP PL, ZARIFIS J et al.: Fibrin D-dimer and β- thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation (1996) 94:425-431.
29. LIP GY, LOWE GD, RUMLEY A, DUNN FG: Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am. Heart J. (1996) 131:724-730.
30. MARIN F, ROLDAN V, CLIMENT VE et al.: Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart (2004) 90:1162-1166. (Pubitemid 39294719)
31. GUSTAFSSON C, BLOMBACK M, BRITTON M, HAMSTEN A, SVENSSON J: Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke (1990) 21:47-51. (Pubitemid 20052529)
32. CHUNG MK, MARTIN DO, SPRECHER D et al.: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation (2001) 104:2886-2891. (Pubitemid 33139098)
33. THAMBIDORAI SK, PARAKH K, MARTIN DO et al.: Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am. J. Cardiol. (2004) 94:805-807.
34. BLACK IW, CHESTERMAN CN, HOPKINS AP, LEE LC, CHONG BH, WALSH WF: Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. (1993) 21:451-457.
35. HART RG, PEARCE LA, ROTHBART RM, MCANULTY JH, ASINGER RW, HALPERIN JL: Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. (2000) 35:183-187. • A longitudinal cohort study comparing patients with intermittent and sustained AF who were treated with aspirin, demonstrating that stroke rate is similar in these two subsets of AF.
36. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. (1994) 154:1449-1457.
37. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med. (1998) 158:1316-1320.
38. SINGER DE, ALBERS GW, DALEN JE, GO AS, HALPERIN JL, MANNING WJ: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126:429S-456S. • The most recent guidelines concerning antithrombotic therapy in AF. (Pubitemid 39302603)
39. FUSTER V, RYDEN LE, CANNOM DS et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation (2006) 114:e257-e354.
40. HART RG, PEARCE LA, MCBRIDE R, ROTHBART RM, ASINGER RW: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke (1999) 30:1223-1229. (Pubitemid 29259178)
41. GAGE BF, WATERMAN AD, SHANNON W, BOECHLER M, RICH MW, RADFORD MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 285:2864-2870. • This study describes a new classification scheme estimating the risk of stroke in AF patients that could be used for therapeutic decision making for antithrombotic therapy in AF. (Pubitemid 32537350)
42. WANG TJ, MASSARO JM, LEVY D et al.: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 290:1049-1056. (Pubitemid 37430445)
43. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Arch. Intern. Med. (1992) 116:6-12.
44. BEYTH RJ, QUINN LM, LANDEFELD CS: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. (1998) 105:91-99.
45. KUIJER PM, HUTTEN BA, PRINS MH, BULLER HR: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch. Intern. Med. (1999) 159:457-460.
46. GAGE BF, YAN Y, MILLIGAN PE et al.: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. (2006) 151:713-719. • This study describes a new classification scheme to evaluate and quantify haemorrhagic risk in AF patients. (Pubitemid 43290267)
47. PETERSEN P, BOYSEN G, GODTFREDSEN J, ANDERSEN ED, ANDERSEN B: Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 1:175-179. (Pubitemid 19038801)
48. THE BOSTON AREA ANTICOAGULATION TRIAL FOR ATRIAL FIBRILLATION INVESTIGATORS: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. (1990) 323:1505-1511.
49. CONNOLLY SJ, LAUPACIS A, GENT M, ROBERTS RS, CAIRNS JA, JOYNER C: Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J. Am. Coll. Cardiol. (1991) 18:349-355.
50. Stroke prevention in atrial fibrillation study: final results. Circulation (1991) 84:527-539.
51. EZEKOWITZ MD, BRIDGERS SL, JAMES KE et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med. (1992) 327:1406-1412.
52. TAYLOR F, COHEN H, EBRAHIM S: Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Br. Med. J. (2001) 322:321-326.
53. HART RG, BENAVENTE O, MC BRIDE R, PEARCE LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Arch. Intern. Med. (1999) 131:492-501.
54. GULLOV AL, KOEFOED BG, PETERSEN P et al.: Fixed minidose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch. Intern. Med. (1998) 158:1513-1521. (Pubitemid 28340984)
55. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet (1994) 343:687-691. (Pubitemid 24087846)
56. PETERSEN P, BOYSEN G, GODTFREDSEN J, ANDERSEN ED, ANDERSEN B: Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 1:175-179. (Pubitemid 19038801)
57. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study: the SPAF III writing committee for the stroke prevention in atrial fibrillation investigators. JAMA (1998) 279:1273-1277.
58. HELLEMONS BS, LANGENBERG M, LODDER J et al.: Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumadin with aspirin. Br. Med. J. (1999) 319:958-964.
59. PEREZ-GOMEZ F, ALEGRIA E, BERJON J et al.: NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J. Am. Coll. Cardiol. (2004) 44:1557-1566.
60. EAFT (EUROPEAN ATRIAL FIBRILLATION TRIAL) STUDY GROUP: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet (1993) 342:1255-1262. (Pubitemid 23338782)
61. MOROCUTTI C, AMABILE G, FATTAPPOSTA F et al.: Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke (1997) 28:1015-1021. (Pubitemid 27209152)
62. SAXENA R, KOUDSTAAL P: Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst. Rev. (2004) 4:CD000187.
63. AGUILAR M, HART R: Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev. (2005) 4:CD001925.
64. AGUILAR MI, HART R: Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev. (2005) 3:CD001927.
65. SEGAL JB, MCNAMARA RL, MILLER MR et al.: Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J. Gen. Intern. Med. (2000) 15:56-67.
66. VAN WALRAVEN C, HART RG, SINGER DE et al.: Oral anticoagulants versus aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 288:2441-2448. • An individual patient meta-analysis from six published randomised control trials in AF patients who were randomly assigned to VKA treatment, aspirin or aspirin plus low-dose oral anticoagulant, showing the superiority of VKA therapy in preventing ischaemic stroke and cardiovascular events. (Pubitemid 35340540)
67. BUNGARD TJ, GHALI WA, TEO KK, MCALISTER FA, TSUYUKI RT: Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. (2000) 160:41-46.
68. MCCORMICK D, GURWITZ JH, GOLDBERG RJ et al.: Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch. Intern. Med. (2001) 161:2458-2463.
69. BRADLEY BC, PERDUE KS, TISDEL KA, GILLIGAN DM: Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am. J. Cardiol. (2000) 85:568-572.
70. BUCKINGHAM TA, HATALA R: Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin. Cardiol. (2002) 25:447-454.
71. SUDLOW M, THOMSON R, KENNY RA, RODGERS H: A community survey of patients with atrial fibrillation: associated disabilities and treatment preference. Br. J. Gen. Pract. (1998) 48:1775-1778.
72. LEVY S, MAAREK M, COUMEL P et al.: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation (1999) 99:3028-3035. (Pubitemid 29270433)
73. BLANN AD, FITZMAURICE DA, LIP GY: Anticoagulation in hospitals and general practice. Br. Med. J. (2003) 326:153-156.
74. WALDO A, BECKER R, TAPSON V, COLAGAN K: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol. (2005) 46:1729-1736. • A retrospective cohort study of in-patients confirming the under use of warfarin even in high-risk patients.
75. LE HEUZEY JY, PAZIAUD O, PIOT O et al.: Cost of care distribution in atrial fibrillation patients: the COCAF study. Am. Heart J. (2004) 147:121-126.
76. THE FALSTAF STUDY GROUP: Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. Pharmacoepidemiol. Drug Saf. (2006). In press.
77. REYNOLDS MW, FAHRBACH K, HAUCH O et al.: Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest (2004) 126:1938-1945. (Pubitemid 39644002)
78. PETERSEN P, GRIND M, ADLER J; SPORTIF II INVESTIGATORS: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. (2003) 41:1445-1451.
79. DE DENUS S, SANOSKI CA, CARLSSON J, OPOLSKI G, SPINLER SA: Rate versus rhythm control in patients with atrial fibrillation: a meta-analysis. Arch. Intern. Med. (2005) 165:258-262. • A meta-analysis of randomised, controlled trials comparing pharmalogical rhythm and rate-control strategies in AF patients, showing that theses two strategies appeared to be at least equivalent in preventing clinical outcomes (death and recurrence).
80. TESTA L, BIONDI-ZOCCAI GG, RUSSO AD, BELLOCCI F, ANDREOTTI F, CREA F: Rate-control versus rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur. Heart J. (2005) 26:2000-2006.
81. WYSE DG, WALDO AL, DIMARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
82. VAN GELDER IC, HAGENS VE, BOSKER HA et al.: A comparison of rate control and rhythm control in patient with recurrent persistent atrial fibrillation. N. Engl. J. Med. (2002) 347:1834-1840.
83. CARLSSON J, MIKETIC S, WINDELER J et al.: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J. Am. Coll. Cardiol. (2003) 41:1690-1696.
84. HOHNLOSER SH, KUCK KH, LILIENTHAL J: Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 356:1789-1794.
85. OPOLSKI G, TORBICKI A, KOSIOR DA et al.: Rate control versus rhythm control in patient with non valvular atrial fibrillation: the results of the Polish How To Treat Chronic Atrial Fibrillation (HOT CAFE). Chest (2004) 126:476-486. (Pubitemid 39093433)
86. SHERMAN DG, KIM SG, BOOP BS et al.: Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (Affirm) study. Arch. Intern. Med. (2005) 165:1185-1191.
87. THE AF-CHF TRIAL INVESTIGATORS: Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am. Heart J. (2002) 144:597-607.
88. HEIST EK, RUSKIN JN: Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog. Cardiovasc. Dis. (2006) 48:256-269.
89. ORAL H, PAPPONE C, CHUGH A et al.: Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N. Engl. J. Med. (2006) 354:934-941.
90. HSU LF, JAIS P, SANDERS P et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med. (2004) 351:2373-2383.
91. REANT P, LAFITTE S, JAIS P et al.: Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation (2005) 112:2896-2903. (Pubitemid 41613884)
92. KLEIN AL, GRIMM RA, MURRAY RD et al.: Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Engl. J. Med. (2001) 344:1411-1420.
93. KLEIN AL, MURRAY RD, GRIMM RA et al.: Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies. Am. J. Cardiol. (2003) 92:161-165.
94. KLEIN AL, GRIMM RA, JASPER SE et al.: Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am. Heart J. (2006) 151:380-389.
95. STELLBRINK C, NIXDORFF U, HOFMANN T et al.: ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin. Circulation (2004) 109:997-1003. • A randomised, prospective, multi-centre trial demonstrating the safety and efficacy of enoxaparin and the non-inferiority to UFH in TEE-guided cardioversion of AF.
96. ROIJER A, ESKILSSON J, OLSSON B: Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. Eur. Heart J. (2000) 21:837-847.
97. YIGIT Z, KUCUKOGLU MS, OKCUN B, SANSOY V, GUZELSOY D: The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J. (2003) 44:369-377. (Pubitemid 41519004)
98. AKDENIZ B, TURKER S, OZTURK V et al.: Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin. Int. J. Cardiol. (2005) 98:49-55.
99. KLEIN AL, JASPER SE, APPERSON-HANSEN C et al.: Safety and efficacy of enoxaparin strategy for cardioversion of atrial fibrillation using transesophageal echocardiography. Preliminary results from the assessement of cardioversion using transesophageal echocardiography. ACUTE II study. Circulation (2005) 112: (1863).
100. BERGE E, ABDELNOOR M, NAKSTAD PH, SANDSET PM: Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet (2000) 355:1205-1210.
101. O'DONNELL MJ, BERGE E, SANDSET PM: Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke (2006) 37:452-455.
102. DOUKETIS JD, JOHNSON JA, TURPIE AG: Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. (2004) 164:1319-1326.
103. KOVACS MJ, KEARON C, RODGER M et al.: Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation (2004) 110:1658-1663. (Pubitemid 39297990)
104. OLSSON SB; EXECUTIVE STEERING COMMITTEE ON BEHALF OF THE SPORTIF III INVESTIGATORS: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362:1691-1698. (Pubitemid 37468318)
105. ALBERS GW, DIENER HC, FRISON L et al.; SPORTIF EXECUTIVE STEERING COMMITTEE FOR THE SPORTIF V INVESTIGATORS: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 293:690-698.
106. LIP GY, EDWARDS S: Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis. Thromb. Res. (2006) 118(3):321-333. • A systematic review and meta-analysis of thromboprophylaxis trial data in AF patients including recent trials with ximelagatran.
107. KAUL S, DIAMOND GA, WEINTRAUBWS: Trials and tribulations of non-inferiority: the ximelagatran experience. J. Am. Coll. Cardiol. (2005) 46:1986-1995.
108. GUREWICH V: Ximelagatran - promises and concerns. JAMA (2005) 293:736-739. (Pubitemid 40216044)
109. DIENER HC: Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc. Dis. (2006) 21:279-293.
110. O'BRIEN CL, GAGE BF: Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA (2005) 293:699-706. (Pubitemid 40216039)
111. Idraparinux sodium: SANORG 34006, SR 34006. Drugs R D. (2004) 5:164-165.
112. LORENZONI R, LAZZERINI G, COCCI F, DE CATERINA R: Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am. Heart J. (2004) 148:6.
113. ACTIVE WRITING GROUP ON BEHALF OF THE ACTIVE INVESTIGATORS: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for the Prevention of Vascular Events (ACTIVEW): a randomised controlled trial. Lancet (2006) 367:1903-1912. (Pubitemid 43842067)
114. EHRLICH JR, HOHNLOSER SH, NATTEL S: Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J. (2006) 27:512-518.
115. BOOS CJ, ANDERSON RA, LIP GY: Is atrial fibrillation an inflammatory disorder? Eur. Heart J. (2006) 27:136-149. (Pubitemid 43069029)
116. WACHTELL K, LEHTO M, GERDTS E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:712-719.
117. WACHTELL K, HORNESTAM B, LEHTO M et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:705-711.
118. MADRID AH, PENG J, ZAMORA J et al.: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin. Electrophysiol. (2004) 27:1405-1410.
119. HEALEY JS, BARANCHUK A, CRYSTAL E et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme Inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. (2005) 45:1832-1839.
120. SCHONBECK U, LIBBY P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents? Circulation (2004) 109:II18-26.
121. SIU CW, LAU CP, TSE HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. (2003) 92:1343-1345.
122. YOUNG-XU Y, JABBOUR S, GOLDBERG R et al.: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. (2003) 92:1379-1383.
123. TVEIT A, GRUNDTVIG M, GUNDERSEN T et al.: Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. (2004) 93:780-782.
124. OSTERMAYER SH, REISMAN M, KRAMER PH, MATTHEWS RV, GRAY WA, BLOCK PC: Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J. Am. Coll. Cardiol. (2005) 46:9-14. • This prospective, non-randomised, multi-centre examines the feasibility and safety of a new device that allows percutaneaous LAA transcatheter occlusion via a transseptal approach.
125. GO AS, HYLEK EM, PHILLIPS KA et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 285:2370-2375. (Pubitemid 32424106)
126. MATCHAR DB, JACOBSON AK, EDSON RG et al.: The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study number 481 - the Home INR Study (THINRS). J. Thromb. Thrombolysis (2005) 19:163-172. (Pubitemid 41149478)
127. SAWICKI PT: A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial: Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA (1999) 281:145-150.
128. SAMSA GP, MATCHAR DB, PHILLIPS DL, MCGRANN J: Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making. J. Thromb. Thrombolysis (2002) 14:103-111. (Pubitemid 36559676)
129. http://www..clinicaltrials.gov/ct/show/nct00129545 National Institute Of Health: Protect Af - Watchman Left Atrial Appendage System For Embolic Protection In Patients With Atrial Fibrillation (September 2006).